Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Neuphoria Therapeutics Inc (NASDAQ: NEUP) closed the day trading at $4.55 up 3.41% from the previous closing price of $4.4. In other words, the price has increased by $3.41 from its previous closing price. On the day, 0.59 million shares were traded. NEUP stock price reached its highest trading level at $4.6699 during the session, while it also had its lowest trading level at $4.35.
Ratios:
For a better understanding of NEUP, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.20. For the most recent quarter (mrq), Quick Ratio is recorded 11.01 and its Current Ratio is at 11.01. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On September 28, 2023, Maxim Group reiterated its Buy rating and also lowered its target price recommendation from $7 to $10.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $54.H.C. Wainwright initiated its Buy rating on January 10, 2022, with a $54 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 21 ’25 when Lynx1 Capital Management LP bought 639,110 shares for $5.14 per share. The transaction valued at 3,283,108 led to the insider holds 875,328 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEUP now has a Market Capitalization of 10727140 and an Enterprise Value of -3334541. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.55 while its Price-to-Book (P/B) ratio in mrq is 0.32. Its current Enterprise Value per Revenue stands at -0.213 whereas that against EBITDA is 20.052.
Stock Price History:
The Beta on a monthly basis for NEUP is 0.52, which has changed by 0.98516583 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, NEUP has reached a high of $21.40, while it has fallen to a 52-week low of $2.16. The 50-Day Moving Average of the stock is -61.42%, while the 200-Day Moving Average is calculated to be -38.72%.
Shares Statistics:
Over the past 3-months, NEUP traded about 1.49M shares per day on average, while over the past 10 days, NEUP traded about 9305010 shares per day. Insiders hold about 4.70% of the company’s shares, while institutions hold 52.52% stake in the company. Shares short for NEUP as of 1760486400 were 13622 with a Short Ratio of 0.01, compared to 1757894400 on 29336. Therefore, it implies a Short% of Shares Outstanding of 13622 and a Short% of Float of 0.58.
Earnings Estimates
. The current rating of Neuphoria Therapeutics Inc (NEUP) is the result of assessments by 1 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$1.31, with high estimates of -$1.31 and low estimates of -$1.31.
Analysts are recommending an EPS of between -$5.26 and -$5.26 for the fiscal current year, implying an average EPS of -$5.26. EPS for the following year is -$3.23, with 2.0 analysts recommending between -$1.21 and -$5.26.
